Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026
Key Highlights
- ➤VOICE trial will present three-times-weekly vadadustat safety results in hemodialysis patients
- ➤Akebia will present Phase 2 praliciguat and ebribafusp alfa rare-kidney-disease data
- ➤Posters will evaluate Vafseo hospitalization costs and cardiovascular outcomes
- ➤Vafseo is approved for dialysis-related CKD anemia in 37 countries
- ➤Vafseo carries boxed warning for death and thrombotic cardiovascular events
WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced upcoming presentations at the American Society of Nephrology Kidney Week 2026 (ASN Kidney Week), which will take place in Denver, CO from October 21-25, 2026. U.S. Renal Care will present the results of the VOICE trial evaluating the safety of three-times-weekly vadadustat compared with an erythropoiesis-stimulating agent (ESA) in patients receiving in-center hemodialysis as a late-breaking presentation. Additionally, Akebia will have multiple poster presentations featuring its rare kidney disease pipeline, including a poster highlighting preclinical research of praliciguat in focal segmental glomerulosclerosis (FSGS), the Phase 2 trial evaluating praliciguat in FSGS, and the Phase 2 basket trial of ebribafusp alfa in complement-mediated kidney diseases. Akebia will also present posters evaluating clinical and economic outcomes associated with Vafseo® (vadadustat).
Get started
Create a free account to read the full story.